Skip Navigation



PEDS Advance Access published online on April 23, 2007

Protein Engineering Design and Selection, doi:10.1093/protein/gzm015
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/5/227    most recent
gzm015v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Humphreys, D. P.
Right arrow Articles by Brand, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Humphreys, D. P.
Right arrow Articles by Brand, H. A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering

David P. Humphreys1,2, Sam P. Heywood1, Alistair Henry1, Layla Ait-Lhadj1, Pari Antoniw1, Roger Palframan1, Kevin J. Greenslade1, Bruce Carrington1, Dominc G. Reeks1, Leigh C. Bowering1, Shauna West1 and Helen A. Brand1

1 UCB-Celltech, 216 Bath Road, Slough, SL1 4EN, UK

2 To whom correspondence should be addressed. E-mail: david.humphreys{at}celltech.ucb-group.com

Antigen-binding fragments (Fab') of antibodies can be site specifically PEGylated at thiols using cysteine reactive PEG–maleimide conjugates. For therapeutic Fab'–PEG, conjugation with 40 kDa of PEG at a single hinge cysteine has been found to confer appropriate pharmacokinetic properties to enable infrequent dosing. Previous methods have activated the hinge cysteine using mildly reducing conditions in order to retain an intact interchain disulphide. We demonstrate that the final Fab–PEG product does not need to retain the interchain disulphide and also therefore that strongly reducing conditions can be used. This alternative approach results in PEGylation efficiencies of 88 and 94% for human and murine Fab, respectively. It also enables accurate and efficient site-specific multi-PEGylation. The use of the non-thiol reductant tris(2-carboxyethyl) phosphine combined with protein engineering enables us to demonstrate the mono-, di- and tri-PEGylation of Fab fragments with a range of PEG size. We present evidence that PEGylated and unPEGylated Fab' molecules that lack an interchain disulphide bond retain very high levels of chemical and thermal stability and normal performance in PK and efficacy models.

Keywords: disulphide engineering/Fab'/PEGylation/periplasm

Received October 16, 2006; revised January 9, 2007; accepted February 14, 2007.


Abbreviations: BSA, bovine serum albumin; ß-ME, ß-mercaptoethanol; ß-MA, ß-mercaptoethylamine; DTT, dithiothreitol; GuHCL, guanidine hydrochloride; GSH, glutathione (reduced); TBP, tris(butyl) phosphine; TCEP, tris(2-carboxyethyl) phosphine; Fab', Fragment antigen binding; PCR, polymerase chain reaction; HPLC, high-performance liquid chromatography; PBS, phosphate-buffered saline; AUC, area under the curve; PEG, polyethylene glycol; PK, pharmacokinetics; LC, light chain; HC, heavy chain; IPTG, isopropyl ß-D-thiogalactopyranoside; EDTA, ethylenediaminetetraacetic.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.